Phase 1 Open Label Safety, Acceptability, Pharmacokinetic and ex Vivo Pharmacodynamic Study of TMC278 Long Acting (LA) Administered Intramuscularly to HIV-1 Seronegative Individuals.

Trial Profile

Phase 1 Open Label Safety, Acceptability, Pharmacokinetic and ex Vivo Pharmacodynamic Study of TMC278 Long Acting (LA) Administered Intramuscularly to HIV-1 Seronegative Individuals.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Rilpivirine (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 26 Jul 2017 Results of multiple dose phase, presented at the 9th International AIDS Society Conference on HIV Science.
    • 06 Apr 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 11 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top